1. Home
  2. TCI vs SGMT Comparison

TCI vs SGMT Comparison

Compare TCI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCI
  • SGMT
  • Stock Information
  • Founded
  • TCI 1983
  • SGMT 2006
  • Country
  • TCI United States
  • SGMT United States
  • Employees
  • TCI N/A
  • SGMT N/A
  • Industry
  • TCI Real Estate
  • SGMT
  • Sector
  • TCI Finance
  • SGMT
  • Exchange
  • TCI Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • TCI 239.1M
  • SGMT 269.2M
  • IPO Year
  • TCI N/A
  • SGMT 2023
  • Fundamental
  • Price
  • TCI $40.27
  • SGMT $9.23
  • Analyst Decision
  • TCI
  • SGMT Strong Buy
  • Analyst Count
  • TCI 0
  • SGMT 5
  • Target Price
  • TCI N/A
  • SGMT $26.60
  • AVG Volume (30 Days)
  • TCI 6.9K
  • SGMT 1.1M
  • Earning Date
  • TCI 08-07-2025
  • SGMT 08-13-2025
  • Dividend Yield
  • TCI N/A
  • SGMT N/A
  • EPS Growth
  • TCI 59.61
  • SGMT N/A
  • EPS
  • TCI 0.92
  • SGMT N/A
  • Revenue
  • TCI $47,452,000.00
  • SGMT N/A
  • Revenue This Year
  • TCI N/A
  • SGMT N/A
  • Revenue Next Year
  • TCI N/A
  • SGMT N/A
  • P/E Ratio
  • TCI $45.33
  • SGMT N/A
  • Revenue Growth
  • TCI N/A
  • SGMT N/A
  • 52 Week Low
  • TCI $25.50
  • SGMT $1.73
  • 52 Week High
  • TCI $46.74
  • SGMT $10.43
  • Technical
  • Relative Strength Index (RSI)
  • TCI 47.78
  • SGMT 66.16
  • Support Level
  • TCI $41.59
  • SGMT $8.49
  • Resistance Level
  • TCI $42.75
  • SGMT $9.95
  • Average True Range (ATR)
  • TCI 1.10
  • SGMT 0.68
  • MACD
  • TCI -0.68
  • SGMT -0.08
  • Stochastic Oscillator
  • TCI -5.62
  • SGMT 86.23

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: